Introducing NUGEN(R) HLD-CD by Arxada: A Game-Changer in Healthcare Disinfection
Delivering Effective Germ Control in Five Minutes
BASEL, CH / ACCESS Newswire / April 24, 2025 / Arxada, a global leader in specialty chemicals and innovative solutions, announces the launch of NUGEN® HLD-CD, a revolutionary healthcare disinfectant. This game-changing solution disinfects medical devices in just five minutes, ensuring that even the most resilient microorganisms, which can withstand harsh conditions, are destroyed.*
NUGEN® HLD-CD is designed to meet the rigorous demands of healthcare environments. Its broad efficacy spectrum and short contact times make it suitable for all critical areas, including operating rooms, isolation areas, and intensive care units where speed and safety are essential.
"We are excited to introduce NUGEN® HLD-CD to the healthcare market," said Uwe Holland, Head of Professional Hygiene EMEA at Arxada. "This solution is a game-changer in disinfection technology for healthcare facilities, providing professionals with a powerful means to improve patient safety and manage infections more effectively."
The European Centre for Disease Prevention and Control reports that these infections result in over 3.5 million cases each year in the EU and EEA, causing more than 90,000 deaths. Effective infection control practices could prevent up to 50% of healthcare-associated infections (HAIs).* NUGEN® HLD-CD delivers powerful protection - arming frontline healthcare teams with a fast, effective tool to stop infections before they spread.
Additionally, NUGEN® HLD-CD is an ideal solution for targeting Clostridium difficile (C. diff) contamination*, a common and challenging pathogen in healthcare settings that spreads via contact with contaminated surfaces.
For more information about NUGEN® HLD-CD and its applications, please visit https://www.arxada.com/en/hygiene/hygiene-emea/nugen-hld-cd or contact hygiene@arxada.com
Media contacts:
Tricia Ryan
External Corporate Communications
Arxada
tricia.ryan@arxada.com
Jane Smith
Marketing Communications, Professional Hygiene
Arxada
jane.smith@arxada.com
About Arxada
Arxada is a global science-based specialty chemicals business creating innovative chemistry and solutions. With customers in more than 100 countries, it achieved sales of CHF 2.0 billion in 2023. The company aims to solve the world's toughest preservation challenges by enhancing sustainability with cleaner, greener solutions. Arxada focuses on multiple end-markets, primarily in: Human Health & Nutrition, Home & Personal Care, Paints & Coatings and Wood Protection, providing a broad portfolio of differentiated products and solutions, supported by its and innovation capabilities, in-depth regulatory know-how and track record in manufacturing and process development. Headquartered in Basel (Switzerland), the company's 3,400 employees contribute to the success of its customers, spanning 24 production sites and 14 R&D centers. To learn more about Arxada, please visit: www.arxada.com and Arxada on LinkedIn.
This product is intended for use as a medical device within the European Union and is sold exclusively to healthcare professionals. It has undergone a conformity assessment to ensure compliance with EU regulations, including the Council Directive 93/42/EEC of 14 June 1993 concerning medical devices. The product is designed to meet the highest standards of safety and performance. Users are advised to follow the instructions for use provided by the manufacturer. The manufacturer is not liable for any misuse or off-label use of the product. All trademarks belong to Arxada or its affiliates. © 2025 Arxada.
*Data on file with Arxada; based on internal and external testing
SOURCE: Enviro Tech Chemical Services, Inc.
View the original press release on ACCESS Newswire
Enviro Tech Chemical Services, Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
RE Royalties Announces Annual Grant of Stock Options and Restricted Share Units20.1.2026 00:00:00 CET | Press release
All amounts in Canadian dollars unless otherwise stated VANCOUVER, BC / ACCESS Newswire / January 19, 2026 / RE Royalties Ltd. (TSXV:RE)(OTCQX:RROYF)(FSE:Y2V) ("RE Royalties" or the "Company") is pleased to announce that, as part of the Company's annual compensation review, the Board of Directors have authorized the grant of 1,195,000 stock options (the "Options") to directors, officers, employees and consultants of the Company. The Options have an exercise price of CAD $0.30 per share and are exercisable for a period of three-years from the date of grant. The Options were granted in accordance with the Company's Stock Option Plan. In addition, the Board of Directors have authorized the grant of an aggregate 800,000 restricted share units ("RSUs") to officers, employees and consultants of the Company. The RSUs were granted in accordance with the Company's RSU Plan in place. "We are pleased to provide these incentive-based equity awards to our valued team members," said Bernard Tan, CEO
GA-ASI and Barzan Holdings Sign MOU19.1.2026 18:00:00 CET | Press release
Companies Will Collaborate on the Development of Advanced Battle Management DOHA, QA / ACCESS Newswire / January 19, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) -- the world leader in unmanned systems - and Barzan Holdings, Qatar's national defence and security leader, signed a Memorandum of Understanding (MOU) to collaborate on the development of advanced Battle Management software capabilities. The signing took place on Monday during the Doha International Maritime Defence Exhibition and Conference (DIMDEX). The MOU provides a framework for cooperation between GA-ASI, GA-Intelligence, and Barzan Holdings to develop software solutions that enhance theater-level situational awareness and enable the efficient processing, correlation, and dissemination of intelligence. These capabilities are intended to support faster, higher-quality decision-making in complex, multi-domain operational environments. For General Atomics, the agreement underscores the strategic importance of
GA-ASI Makes Another Autonomous Aerial Intercept in Company-Funded Demo with MQ-20 Avenger(R)19.1.2026 03:00:00 CET | Press release
SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 18, 2026 / In its latest demonstration of advanced autonomy development, General Atomics Aeronautical Systems, Inc. (GA-ASI) successfully executed a mission autonomy flight using its MQ-20 Avenger® jet equipped with the latest government reference autonomy software. The test included a live engagement between the MQ-20 and an aggressor aircraft flown by an onboard human pilot, highlighting the advanced maturity of autonomous systems, seamless integration of mission elements, and the ability of autonomy to leverage onboard sensors to make independent decisions and execute complex tasks. GA-ASI's Avenger jet has served as a surrogate for Collaborative Combat Aircraft (CCA) for more than five years, both before and since the arrival of GA-ASI's purpose-built XQ-67A and YFQ-42A aircraft. The recent Avenger demo began with planning in the Human-Machine Interface (HMI), followed by loading the mission profile onto the MQ-20. Once airborne, th
GoodData Accelerates in Q4 with Product Innovation and Business Growth15.1.2026 10:55:00 CET | Press release
SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 15, 2026 / GoodData, a leading AI-native decision intelligence platform, today announced strong Q4 results driven by record product development velocity, the launch of its Intelligence Layer for trustworthy AI, and continued expansion across the financial services sector. The quarter underscored GoodData's commitment to delivering inclusive, governed AI at scale, marked by significant accessibility milestones and sustained adoption among global enterprises. Business highlights GoodData's momentum accelerated throughout Q4, fuelled by a surge in development activity and deepening strategic partnerships. The company delivered a 50% year-on-year increase of product releases in Q4 2025 compared to Q4 2024, with a three-fold increase in AI-focused development activity in agentic workflows in H2. "Our performance in Q4 shows that speed and trust are not mutually exclusive," said Roman Stanek, CEO and Founder of GoodData. "With the launch
A True Empowerer - AGFA HealthCare Radiates Imaging Innovation at ECR 202615.1.2026 09:00:00 CET | Press release
In Vienna, Enterprise Imaging offers the "Clinician-First" approach to keeping radiologists in their flow, spotlighting the human behind the innovation and empowering them to work in comfort with their technology. MORTSEL, BE / ACCESS Newswire / January 15, 2026 / At ECR 2026, AGFA HealthCare will unveil its latest imaging innovations that transform the clinician experience and drive smarter care. Turning knowledge into action, AGFA delivers advancements which empower radiologists with seamless workflows, intelligent automation and tailored diagnostic environments. Under the event 2026 theme "Rays of Knowledge", AGFA is ready to demonstrate how we have reached the summit of Empowerer - adopting the ‘Clinician-First' approach, which demonstrates a profound understanding of the clinician's challenges and workflow realities. "Clinician First is more than a message - it's a mindset", says Andrea Polticchia, Regional President for Southern Europe, AGFA HealthCare. "This approach reflects ou
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom